Live Breaking News & Updates on Lucid Diagnostics Daily

Stay updated with breaking news from Lucid diagnostics daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Head to Head Analysis: Lucid Diagnostics (NASDAQ:LUCD) & Shockwave Medical (NASDAQ:SWAV)

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) and Shockwave Medical (NASDAQ:SWAV – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends. Volatility and Risk Lucid Diagnostics has a beta […] ....

United States , New York , Santa Clara , Pavmed Inc , Shockwave Medical Inc , Lucid Diagnostics Inc , Lucid Diagnostics , Get Free Report , Shockwave Medical , Given Lucid Diagnostic , Diagnostics Inc , Esoguard Esophageal , Esocheck Esophageal Cell , Shockwave Crescendo , Lucid Diagnostics Daily ,

Cantor Fitzgerald Equities Analysts Reduce Earnings Estimates for Lucid Diagnostics Inc. (NASDAQ:LUCD)

Lucid Diagnostics Inc. (NASDAQ:LUCD – Free Report) – Investment analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for shares of Lucid Diagnostics in a report issued on Wednesday, May 15th. Cantor Fitzgerald analyst R. Osborn now expects that the company will earn ($1.06) per share for the year, down from their […] ....

United States , Lucid Diagnostics Inc , Needham Company , Cantor Fitzgerald , Lucid Diagnostics , Free Report , Lucid Diagnostic , Get Free Report , Diagnostics Stock Down , Diagnostics Inc , Esoguard Esophageal , Esocheck Esophageal Cell , Lucid Diagnostics Daily ,

Needham & Company LLC Reaffirms "Buy" Rating for Lucid Diagnostics (NASDAQ:LUCD)

Needham & Company LLC reaffirmed their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $2.50 price objective on the stock. Separately, Cantor Fitzgerald reduced their price target on shares of Lucid Diagnostics from $3.80 to $3.00 […] ....

United States , Lucid Diagnostics Inc , Cantor Fitzgerald , Needham Company , Lucid Diagnostics , Free Report , Diagnostics Stock Down , Get Free Report , Diagnostics Inc , Esoguard Esophageal , Esocheck Esophageal Cell , Lucid Diagnostics Daily ,

Lucid Diagnostics (NASDAQ:LUCD) Earns Buy Rating from Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD – Free Report) in a research report report published on Monday, Benzinga reports. Needham & Company LLC currently has a $2.50 price objective on the stock. Separately, Cantor Fitzgerald lowered their target price on shares of Lucid Diagnostics from $3.80 to […] ....

United States , Lucid Diagnostics Company Profile , Lucid Diagnostics Inc , Cantor Fitzgerald , Needham Company , Lucid Diagnostics , Free Report , Diagnostics Stock Down , Get Free Report , Diagnostics Inc , Esoguard Esophageal , Esocheck Esophageal Cell , Lucid Diagnostics Daily ,

Lucid Diagnostics (NASDAQ:LUCD) & LeMaitre Vascular (NASDAQ:LMAT) Critical Survey

Lucid Diagnostics (NASDAQ:LUCD) & LeMaitre Vascular (NASDAQ:LMAT) Critical Survey
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

United States , New York , Vascutech Inc , Lemaitre Vascular , Pavmed Inc , Lucid Diagnostics Inc , Lemaitre Vascular Inc , Lucid Diagnostics , Get Free Report , Given Lucid Diagnostic , Maitre Vascular , Diagnostics Inc , Esoguard Esophageal , Esocheck Esophageal Cell , Lucid Diagnostics Daily ,